APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Phase Ib/II study of safety, tolerability, efficacy and PK of APG-2575 as a single agent or
in combination with other therapeutic agents including ibrutinib or rituximab.